HIIT vs. MICT Training Study
- Conditions
- SedentaryLifestyle
- Interventions
- Other: Exercise intervention
- Registration Number
- NCT05513300
- Lead Sponsor
- Stanford University
- Brief Summary
The purpose of this study is to compare the impact of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) on human health outcomes in healthy sedentary subjects, over 12 weeks of exercise training.
The investigators will compare several health parameters, such as changes in multiomics profile, cardiorespiratory fitness, muscle strength, and body composition, before and after 12-week interventions of either HIIT or MICT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 135
- Be 18-65 years of age
- Not be pregnant or lactating in the last 12 months, or planning to become pregnant for the next 4 months. A pregnancy test will be performed on the day of DXA scan in women of child-bearing potential. Not be post-partum during the last 12 months.
- Be generally healthy (a list of medical conditions and/or medication that will exclude participants is listed in the section below)
- Body mass index (BMI) > 18 to < 40 kg/m2
- Sedentary in the past year, defined as regular (structured) endurance exercise (e.g., brisk walking, jogging, running, cycling, elliptical, or swimming activity that results in feelings of increased heart rate, rapid breathing, and/or sweating) or resistance training (resulting in muscular fatigue), no more than 1 hour per week.
Persons bicycling as a mode of transportation to and from work >1 day/week etc. will not be considered sedentary.
Leisure walkers are included unless they meet the heart rate, breathing, and sweating criteria noted above.
- Exclusion criteria are confirmed by either self-report (i.e., medical and medication histories reviewed by a clinician), screening tests performed by the study team, and/or clinician judgment as specified for each criterion.
A person may not participate in this study if any of the following applies to them:
- Diabetes (self-report and screening tests), which includes: i) treatment with any hypoglycemic agents (self-report, even for non-diabetic reasons) or ii) fasting glucose >125 or A1c >6.4 (screening test).
- Abnormal bleeding or coagulopathy (self-report): history of a bleeding disorder or clotting abnormality.
- Thyroid disease (screening test):
Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory. Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for more than 3 months prior to retesting.
Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment.
-
Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD) and/or pulmonary hypertension.
-
Metabolic bone disease (self-report): i) history of non-traumatic fracture from a standing height or less and/or ii) current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen.
-
Estrogens, progestins (self-report): supplemental, replacement or therapeutic use of estrogens or progestins within the last 6 months, other than birth control or to control menopausal symptoms.
-
Elevated blood pressure readings (screening test): i) age < 60 years: any history of hypertension; ii) age > 60 years: resting blood pressure reading higher than 150/90 mmHg.
-
Cardiovascular diseases (self-report, screening tests, and clinician judgment):
i) Congestive heart failure, pericardial effusion, coronary artery disease, mild valvular heart disease, congenital heart disease, significant arrhythmia(at rest or with exercise), stroke, or symptomatic peripheral artery disease (self-report, screening test) ii) Positive stress induced wall motion abnormalities.
-
Unexplained syncope.
-
Abnormal blood lipid profile (screening test): either fasting triglycerides >500 mg/dLand/or LDL cholesterol (LDL-C) >190mg/dL.
-
History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years. Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months.
-
Chronic infection: i) infections requiring chronic antibiotic or anti-viral treatment; ii) Human Immunodeficiency Virus; iii) individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded.
-
Liver enzyme tests (alanine transaminase, aspartate transaminase) (screening test) >2 times the laboratory upper limit of normal.
-
Chronic renal insufficiency (screening test): estimated glomerular filtration rate <60 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation
-
Hematocrit (screening) >3 points outside of the local normal laboratory ranges for women and men
-
Whole blood donation in the last 3 months or plans for blood donation during the entire protocol period. Platelet or plasma donation in the last week or plans for platelet or plasma donation during the entire protocol period
-
Individuals receiving any active treatment for autoimmune disorders (including monoclonal antibodies) within the last 6 months.
-
Alcohol consumption (self-report): i) more than 7 drinks per week for women and more than 14 drinks per week for men; ii) history of binge drinking.
-
Consume of tobacco, e-cigarette, nicotine products, and/or marijuana more than 3 days a week.
Shift workers: night shift work in the last 6 months or planning night shift work during the study period.
- Hospitalization for any psychiatric condition within one year (self-report).
- Weight change (intentional or not) over the last 6 months of >5% of body weight or plan to lose or gain weight during the study.
- Inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, connective tissue disease including lupus, systemic lupus.
- Any musculoskeletal or ligamentous injury, amputation or congenital neurological defect that, in the opinion of the team clinician, would negatively impact or mitigate participation in and completion of the protocol.
- Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric or other conditions that, in the opinion of the team clinician, would preclude participation and successful completion of the protocol. Any other blood tests value outside of normal range if that indicates a condition that might preclude participation in the study.
- Mental incapacity and/or cognitive impairment on the part of the participant that would inhibit adequate understanding of or cooperation with the study protocol.
EXCLUSIONS FOR MEDICATION USE:
Use of any new drug in the last 3 months or dose change for any drug in the last within 3 months
Participants will be excluded if they are taking any of the medication listed below:
Anticoagulants Antiarrhythmics Antiplatelet drugs (other than aspirin <100 mg/day) Beta blockers Lipid-lowering medications Chronic use of medium- or long-acting sedatives and hypnotics (short-acting non-benzodiazepine sedative-hypnotics are allowed) Two or more drugs for depression Mood stabilizers Antiepileptic drugs Stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs Anti-psychotic drugs Muscle relaxants Chronic oral steroids Burst/taper oral steroids more than once in the last 12 months B2-agonists, allowed if on stable dose at least 3 months 5-alpha reductase inhibitors Daily phosphodiesterase type 5 inhibitor use Androgenic anabolic steroids, anti-estrogens, anti-androgens Growth hormone, insulin like growth factor-I, growth hormone releasing hormone Any drugs used to treat diabetes mellitus or to lower blood glucose Any drugs used specifically to induce weight loss Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy Narcotics and narcotic receptor agonists Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen more than 3 days a week Anti-malarials High-potency topical steroids Continuous use of antibiotics or other anti-infectives Monoclonal antibodies Any other medications that, in the opinion of local clinicians, would negatively impact or mitigate full participation and completion.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description MICT group Exercise intervention Participants randomized in this group will be assigned to 12 weeks of moderate-intensity continuous training. HIIT group Exercise intervention Participants randomized in this group will be assigned to 12 weeks high intensity interval training.
- Primary Outcome Measures
Name Time Method Clinical markers Baseline; 12 weeks Changes in measured lipids in mg/dL including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides
Cardiopulmonary Exercise Testing Baseline; 12 weeks Change in VO2 max after training, measured during cardiopulmonary exercise testing
Lipidome after 12-week intervention Baseline; 12 weeks Change in lipids measured in biospecimens after 12 weeks of training
Epigenome after 12-week intervention Baseline; 12 weeks Change in epigenome measured in biospecimens after 12 weeks of training
Transcriptome after 12-week intervention Baseline; 12 weeks Change in mRNA-based expression measured in biospecimens after 12 weeks of training
Metabolome after 12-week intervention Baseline; 12 weeks Change in metabolites measured in biospecimens after 12 weeks of training
Proteome after 12-week intervention Baseline; 12 weeks Change in protein measured in biospecimens after 12 weeks of training
- Secondary Outcome Measures
Name Time Method Transcriptome after acute exercise Baseline; 12 weeks Change in mRNA-based expression measured in biospecimens after acute exercise tests
Proteome after acute exercise Baseline; 12 weeks Change in protein measured in biospecimens after acute exercise tests
Leg strength Baseline; 12 weeks Change in leg strength measured by Biodex
Exercise Motivation Baseline; 12 weeks Change in exercise motivation level measured by motivation for physical activity (RM 4-FM) questionnaire. RM 4-FM scores four different dimensions of motivation, each on a 0-7 point composite scale, with higher scores indicating stronger motivation.
Lipidome after acute exercise Baseline; 12 weeks Change in lipids measured in biospecimens after acute exercise tests
Lean muscle mass Baseline; 12 weeks Change in lean muscle mass in kg measured by dual-energy x-ray absorptiometry
Fat mass Baseline; 12 weeks Change in fat mass in kg measured by dual-energy x-ray absorptiometry
Blood glucose Baseline; 12 weeks Change in blood glucose in mg/dl profile measured with continuous glucose monitor
LV diastolic volume Baseline; 12 weeks Change in LV diastolic volume measured by echocardiogram
Metabolome after acute exercise Baseline; 12 weeks Change in metabolites measured in biospecimens after acute exercise tests
Resting heart rate Baseline; 12 weeks Change in resting heart rate measured by wearable devices
Metagenome profile Baseline; 12 weeks Change in metagenome profile from stool microbiome kit
Ejection fraction Baseline; 12 weeks Change in ejection fraction measured by echocardiogram
Depression Baseline; Week 4, 8, 12 Change in depression presence and/or severity measured by Patient Health Questionnaire-8, an 8-item scale providing a 0-24 point composite score, with higher scores indicating greater severity.
Perceived Stress Baseline; Week 4, 8, 12 Change in perceived stress measured by Perceived Stress Scale-10, a 10-item scale providing a 0-40 point composite score, with higher scores indicating greater perceived stress.
Hand grip strength Baseline; 12 weeks Change in hand grip strength measured by Biodex
Left ventricle (LV) mass Baseline; 12 weeks Change in left ventricle mass measured by echocardiogram
Exercise Self-Efficacy Baseline; 12 weeks Change in exercise self-efficacy measured by Exercise Self Efficacy questionnaire, , a 9-item scale providing a 9-28 point composite score, with higher scores indicating higher self-efficacy for exercise.
Epigenome after acute exercise Baseline; 12 weeks Change in epigenome measured in biospecimens after acute exercise tests
Generalized Anxiety Baseline; Week 4, 8, 12 Change in anxiety presence and/or severity measured by Generalized Anxiety Disorder-7 , a 7-item scale providing a 0-21 point composite score, with higher scores indicating greater anxiety.
Trial Locations
- Locations (1)
Stanford University
🇺🇸Stanford, California, United States